Vicadrostat

Vicadrostat (BI 690517) is Boehringer Ingelheim's selective aldosterone synthase inhibitor. The thesis has been materially damaged in the last 60 days. On September 15, 2026, Boehringer discontinued the lead Phase 3 trial, EASi-KIDNEY (NCT06531824, n=8,371), on recommendation from the independent Data Monitoring Committee after accumulating data showed no meaningful clinical benefit on the primary cardiorenal composite endpoint when vicadrostat was added to empagliflozin in chronic kidney disease [2][14]. The discontinuation was framed as efficacy futility, not safety. Three Phase 3 trials continue under separate DMCs: EASi-ALPINE in HFrEF (NCT06935370, n=4,200), EASi-SUMMIT in HFpEF (NCT06424288, n=6,712), and EASi-PROTKT in type 2 diabetes with established cardiovascular disease (NCT07064473, n=11,800) [3][4][5]. Every remaining Phase 3 trial pairs vicadrostat with empagliflozin (Jardiance), which generated ~$13B in global sales in 2024 ($9.7B Boehringer Ingelheim + $3.3B Eli Lilly), making it one of the top-five selling drugs globally [15][16]. The commercial play was lifecycle extension of Jardiance. With the CKD indication now gone, the surviving case rests on heart failure (where the anti-fibrotic rationale is cleanest in HFpEF) and the diabetes-plus-CVD population. Meanwhile the mechanism has been class-validated by baxdrostat (Baxfendy, AstraZeneca), FDA-approved May 18, 2026 for uncontrolled hypertension [17] - which hands first-mover pricing in the class to a competitor and compresses the window for vicadrostat even on a successful HF readout.

Vicadrostat is a novel compound with no regulatory approval anywhere and no FDA designations (breakthrough, fast track, orphan) as of October 2026. The program is now three Phase 3 trials, not four. EASi-KIDNEY (NCT06531824) was discontinued September 15, 2026 for futility on the primary endpoint; this is a confirmed negative Phase 3 readout, not a signal yet to come [2][14]. EASi-ALPINE in HFrEF (NCT06935370, n=4,200) and EASi-SUMMIT in HFpEF (NCT06424288, n=6,712) continue to recruit; both are event-driven [4][5]. EASi-PROTKT in T2D plus hypertension plus established CVD (NCT07064473, n=11,800) is also recruiting [3]. The Phase 3 dose selected is 10 mg once daily, based on Phase 2 TARGET program dose-ranging that showed urine ACR reductions versus placebo of -9% (3 mg), -40% (10 mg), and -33% (20 mg) on top of empagliflozin [13][18]. A Phase 1 bioequivalence study of a fixed-dose vicadrostat/empagliflozin combination tablet (NCT07845630) is running, consistent with a single-pill lifecycle extension plan - likely also intended to establish a new formulation patent [6]. On that patent point: Jardiance's U.S. composition-of-matter patent for empagliflozin expired in 2025, but method-of-use patents and pediatric exclusivity extend effective protection to roughly 2027-2031 depending on indication and jurisdiction [19]. This is the window the fixed-dose combination is designed to defend. Boehringer Ingelheim is privately held, so there are no SEC filings. Lilly's quarterly 10-Qs disclose their share of Jardiance sales. A realistic HF regulatory filing is now 2029-2030 under a successful readout scenario, pushed back from the pre-discontinuation base case.

Aldosterone is a hormone the adrenal glands produce. It tells the kidneys to hold onto sodium and water, which raises blood pressure, and over time it drives scarring in the heart and kidneys. In heart failure and chronic kidney disease, aldosterone is chronically elevated, and that is what mineralocorticoid receptor antagonists (MRAs) like spironolactone and finerenone block downstream at the receptor [1]. Those drugs work: RALES, EPHESUS, FIDELIO-DKD, and FIGARO-DKD all showed cardiovascular and renal benefits [1]. The mechanism is well validated by drugs already on the market. Vicadrostat takes a different route. Instead of blocking aldosterone's receptor, it blocks aldosterone synthase (CYP11B2), the enzyme that makes aldosterone in the first place [1]. The hard part is selectivity. CYP11B2 is 93% identical to CYP11B1, the enzyme that makes cortisol, your main stress hormone. The selectivity challenge is real. Osilodrostat (Isturisa), originally developed by Novartis as a hypertension drug, had to be abandoned for that use because its CYP11B1 cross-reactivity suppressed cortisol production. Novartis then repurposed osilodrostat for Cushing's disease, where suppressing cortisol is exactly the therapeutic goal, and it was approved for Cushing's in 2020 with a label expansion in April 2025. Osilodrostat is a cautionary tale about selectivity, not about a failed molecule - the molecule found an indication where its weakness became an asset. Vicadrostat shows roughly 100-fold selectivity for CYP11B2 over CYP11B1 in clinical pharmacology studies, which is the property that makes it viable where osilodrostat could not go in hypertension [1][10]. The theoretical advantage over MRAs is cleaner tolerability. MRAs cause gynecomastia (spironolactone) and hyperkalemia (all of them), which limits dose escalation and discontinues patients. The CKD discontinuation does not refute the mechanism - baxdrostat's hypertension approval validates aldosterone synthase inhibition as a druggable class. What EASi-KIDNEY appears to refute is that incremental cardiorenal benefit on top of empagliflozin in CKD is achievable at the 10 mg dose, in the population and endpoint tested, within the time horizon the DMC reviewed.

The remaining Phase 3 trials are all placebo-controlled, all adding vicadrostat 10 mg on top of empagliflozin plus guideline-directed background therapy. EASi-KIDNEY (NCT06531824, n=8,371) was the lead and was discontinued September 15, 2026 for futility on the composite cardiorenal primary endpoint (kidney disease progression, hospitalization for heart failure, or cardiovascular death) [2][14]. Of the three trials still running: EASi-ALPINE (NCT06935370, n=4,200) targets heart failure with reduced ejection fraction (HFrEF). EASi-SUMMIT (NCT06424288, n=6,712) targets heart failure with preserved ejection fraction (HFpEF), making it the larger and mechanistically more interesting of the two HF trials - HFpEF is the harder-to-treat population where fibrosis dominates pathophysiology, which is where vicadrostat's anti-fibrotic mechanism has the cleanest theoretical fit. Both HF trials use CV death, HF hospitalization, or urgent HF visit as the composite primary [4][5]. EASi-PROTKT (NCT07064473, n=11,800) enrolls T2D plus hypertension plus established CVD, primary endpoint time to CV death or heart failure event [3]. The design is sound on paper. Placebo-controlled on top of standard of care (which now includes SGLT2) is the regulatory standard. Composite endpoints match what finerenone used to win FIDELIO-DKD and FIGARO-DKD. Event-driven analysis gives statistical power without needing fixed follow-up windows. The design concern - incremental benefit over empagliflozin - is now a demonstrated problem, not a theoretical one. Empagliflozin itself reduces CV death and HF hospitalization by roughly 25-35% in these populations. In CKD, that residual risk was apparently not addressable by adding vicadrostat. In HF, especially HFpEF, the anti-fibrotic rationale is stronger and the SGLT2 effect size is smaller, so there is more room to add benefit. In the T2D+CVD population, the hypothesis is messier because SGLT2 covers most of the diabetic cardiorenal risk already.

Our model estimates a 55% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 57%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by larger-than-typical enrollment for this phase, strong earlier-phase results, and more secondary endpoints than usual; it is held back by heavier-than-usual blinding. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is now realized for CKD and remains the central question for the surviving indications. Empagliflozin shifts the cardiorenal risk curve substantially, and EASi-KIDNEY demonstrated that at least in CKD, 10 mg vicadrostat does not add detectable incremental benefit at the DMC's interim look. The remaining HF and T2D trials must either show a different mechanism of residual risk reduction operating in those populations (plausible in HFpEF given fibrosis biology) or accept that the overall program is incremental-benefit-constrained. Safety risk is hyperkalemia. Blocking aldosterone synthesis raises serum potassium the same way MRAs do, and the Phase 2 TARGET program saw dose-dependent increases [1][13]. The Phase 3 HF program will need to show the hyperkalemia profile is at least as good as finerenone's. A secondary safety question is cortisol: 100-fold CYP11B2 selectivity is strong but not infinite, and chronic dosing in 11,800 patients will eventually surface whether outlier cortisol suppression emerges. Execution risk is low given sponsor quality - Boehringer runs trials cleanly, and the EASi-KIDNEY discontinuation was a disciplined DMC-led futility stop, not an operational failure. Commercial risk has worsened sharply. Baxfendy (baxdrostat) is now the first FDA-approved aldosterone synthase inhibitor and will reach cardiologists and primary care before vicadrostat does, in a label (uncontrolled hypertension) that overlaps substantially with the cardiovascular comorbidities of the HF and T2D+CVD populations [17]. Payers will ask what a vicadrostat-empagliflozin fixed-dose combination offers that is not available by prescribing generic empagliflozin plus Baxfendy separately once Jardiance genericizes between 2027-2031 [19]. A 20% reduction in CV death on HFpEF background would still be commercially meaningful. A 10% composite reduction would struggle for reimbursement.

Watch, but with lowered expectations. The lifecycle extension thesis is wounded. The two or three cleanest signals to track from here: First, EASi-SUMMIT (HFpEF) is now the single most important readout in the vicadrostat program, both because HFpEF is the mechanistically most favorable population for anti-fibrotic add-on and because HFpEF is the larger addressable market than HFrEF. Expected timing is 2028-2029 given the n=6,712 enrollment and event-driven design, pushed back by at least 12 months from pre-discontinuation estimates. Second, EASi-ALPINE (HFrEF) will likely read out on a similar or slightly earlier timeline. A positive HFrEF signal rescues the program commercially. A negative HFrEF signal with a positive HFpEF signal would still support an HFpEF filing but would narrow the label. Third, EASi-PROTKT (T2D+CVD) is the furthest out (2029-2030) and the most crowded commercially; a win here matters less than a win in HF. The specific data points to watch at each HF readout: hazard ratio for the composite primary (HR under 0.80 is a clear win, 0.80-0.90 is reimbursement-ambiguous, above 0.90 or missed is a program-ender), and hyperkalemia rate relative to finerenone. Jardiance patent cliff timing (effective U.S. protection to roughly 2027-2031) [19] determines whether a fixed-dose combination approved around 2029-2030 lands in a meaningful commercial window or against generic empagliflozin. The DO NOT WATCH signals are now resolved: baxdrostat's hypertension readout and approval already happened (May 2026) [17], and EASi-KIDNEY's readout already happened (September 2026 futility stop) [14]. For investors modeling the Lilly side of the alliance, note that Lilly discloses its ~$3.3B Jardiance share quarterly; a successful HF readout would materially extend that revenue line past the composition-of-matter cliff.